To the extent possible under law, the person who associated CC0 with this work has waived all copyright and related or neighboring rights to this work.
General Information
DRAVP ID DRAVPe02325
Peptide Name DFTavP2
Sequence RWLRGLLSGLLRRLLS
Sequence Length 16
UniProt ID No entry found
Taxon ID None
Source Designed In-silico (Ab-initio) by using database filtering technology
Validation In-Silico
Origin Information
Gene Name/ID Not Available
GenBank Not Available
Amino Acid position Not Available
Domain Accession ID Not Available
Nucleotide sequence ID Not Available
Molecular Type Not Available
Chromosomal Position Not Available
Activity Information
Target Organism EBOV
Assay N/A
Activity
Hemolytic Activity No hemolysis information or data found in the reference(s) presented in this entry
Cytotoxicity No cytotoxicity information found in the reference(s) presented
Binding Target Glycoprotein.
Mechanism DFTavP2 likely combats the Ebola virus by interacting with viral glycoproteins or host cell receptors, thereby inhibiting viral entry into host cells. It may disrupt viral membranes, compromising the virus's structural integrity and function. The peptide could also interfere with the virus's replication machinery by binding to viral RNA or essential proteins. Overall, these mechanisms highlight DFTavP2's potential in blocking critical stages of the Ebola virus lifecycle
Structure Information
PDB ID None
Linear/Cyclic Linear
N-terminal Modification Free
C-terminal Modification Free
Other Modification None
Stereochemistry L
Physicochemical Information
Formula C87H153N29O19
Absent amino acids ACDEFHIKMNOPQTUVY
Common amino acids L
Mass 1909.35
Pl 12.48
Basic residues 4
Acidic residues 0
Hydrophobic residues 8
Net charge 4
Boman Index 1.73
Hydrophobicity 0.331
Aliphatic Index 170.62
Half Life
Extinction Coefficient cystines 5500
Absorbance 280nm 2.881
Polar residues 6
Literature Information
Literature 1
Title Improved Database Filtering Technology Enables More Efficient Ab Initio Design of Potent Peptides against Ebola Viruses.
Pubmed ID 35631348
Reference Pharmaceuticals (Basel). 2022;15(5).
Author Ripperda T, Yu Y, Verma A, et al.
To the extent possible under law, the person who associated CC0 with this work has waived all copyright and related or neighboring rights to this work.